Back to search results

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

IsraelRecruitingPHASE3

Conditions

Von Hippel-Lindau Disease · Malignant Neoplasms

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Beth Israel Deaconess Medical Center ( Site 0107), Boston, Massachusetts, United States

    Study coordinator · 617-667-7000

  • Dana-Farber Cancer Institute ( Site 0105), Boston, Massachusetts, United States

    Study coordinator · 617-632-3466

  • Karmanos Cancer Center ( Site 0108), Detroit, Michigan, United States

    Study coordinator · 800-527-6266

  • Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100), Philadelphia, Pennsylvania, United States

    Study coordinator · 215-360-0737

  • SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States

    Study coordinator · 615-329-7274

  • START San Antonio ( Site 0104), San Antonio, Texas, United States

    Study coordinator · 210-593-5265

  • Fred Hutchinson Cancer Center ( Site 0106), Seattle, Washington, United States

    Study coordinator · 206-606-7341

  • St George Hospital-Oncology Clinical Research Unit ( Site 2701), Kogarah, New South Wales, Australia

    Study coordinator · +6191133830

  • UZ Leuven ( Site 0900), Leuven, Vlaams-Brabant, Belgium

    Study coordinator · +32 (0)16 34 69 12

  • Département clinique de médecine de laboratoire du CHUM ( Site 0001), Montreal, Quebec, Canada

    Study coordinator · 5143408222x24572

  • CIDO SpA ( Site 0305), Temuco, Araucania, Chile

    Study coordinator · +56452657374

  • FALP ( Site 0300), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56224457254

  • Oncovida ( Site 0303), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56225992900

  • ONCOCENTRO APYS ( Site 0302), Viña del Mar, Valparaiso, Chile

    Study coordinator · +56323320861

  • Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 1000), Olomouc, Czechia

    Study coordinator · 588441111

  • Herlev and Gentofte Hospital ( Site 1200), Herlev, Capital Region, Denmark

    Study coordinator · +45 38688798

  • Tampereen yliopistollinen sairaala ( Site 1305), Tampere, Pirkanmaa, Finland

    Study coordinator · +358331163082

  • Hôpitaux Universitaires de Strasbourg ( Site 1702), Strasbourg, Bas-Rhin, France

    Study coordinator · +33368766767

  • Institut Claudius Regaud ( Site 1703), Toulouse, Haute-Garonne, France

    Study coordinator · +33531155050

  • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 1501), Budapest, Hungary

    Study coordinator · +3612248600 #3162

  • Rambam Health Care Campus ( Site 1600), Haifa, Israel

    Study coordinator · +97247772688

  • Hadassah Medical Center ( Site 1604), Jerusalem, Israel

    Study coordinator · +97226777333

  • Rabin Medical Center ( Site 1602), Petah Tikva, Israel

    Study coordinator · +97239377377

  • Sheba Medical center ( Site 1601), Ramat Gan, Israel

    Study coordinator · +972035303030

  • Sourasky Medical Center ( Site 1603), Tel Aviv, Israel

    Study coordinator · + 972 3 6947284

  • Kyushu University Hospital ( Site 3101), Fukuoka, Japan

    Study coordinator · +81-92-641-1151

  • Isala, locatie Zwolle ( Site 1902), Zwolle, Overijssel, Netherlands

    Study coordinator · +31886246040

  • Auckland City Hospital ( Site 3000), Auckland, New Zealand

    Study coordinator · 093074949

  • Zakład Diagnostyki Laboratoryjnej, Centrum Onkologii ( Site 2000), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

    Study coordinator · +48523743862

  • N.N. Blokhin NMRCO ( Site 2101), Moscow, Moscow, Russia

  • Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100), Saint Petersburg, Sankt-Peterburg, Russia

  • Samsung Medical Center ( Site 2902), Gangnam, Seoul, South Korea

    Study coordinator · +82-2-3410-1767

  • Severance Hospital, Yonsei University Health System ( Site 2901), Seodaemun-gu, Seoul, South Korea

    Study coordinator · +82-2-2228-8138

  • Asan Medical Center ( Site 2900), Seoul, South Korea

    Study coordinator · +82-2-3010-5977

  • Hospital Universitari Vall d'Hebron ( Site 2300), Barcelona, Spain

    Study coordinator · +34934894350

  • Hospital Universitario 12 de Octubre ( Site 2301), Madrid, Spain

    Study coordinator · +34 91 390 83 39

  • Taipei Veterans General Hospital ( Site 2800), Taipei, Taiwan

  • ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601), Dnipropetrovsk, Dnipropetrovsk Oblast, Ukraine

  • CNCE Precarpathian Clinical Oncologic Center ( Site 2600), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

  • The Beatson West of Scotland Cancer Centre ( Site 2505), Glasgow, Glasgow City, United Kingdom

    Study coordinator · +441413017064

  • St Bartholomew's Hospital ( Site 2500), London, London, City of, United Kingdom

    Study coordinator · +442072533411

  • ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 2502), London, London, City of, United Kingdom

    Study coordinator · +442087523829

  • Imperial College Healthcare NHS Trust, Charing Cross Hospital ( Site 2504), London, London, City of, United Kingdom

    Study coordinator · +44 203 311 5308

  • The Christie NHS Foundation Trust ( Site 2501), Manchester, United Kingdom

    Study coordinator · 0161 918 7884
Study leads

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

View source on ClinicalTrials.gov(opens in a new tab)